Apimeds notifies SEC of late 10-Q for Q1 2026

Apimeds Pharmaceuticals US, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 because it is finalizing the quarter-end financial statements and requires additional time.

Rhea-AI Filing Summary

Apimeds Pharmaceuticals US, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 because it is finalizing the quarter-end financial statements and requires additional time. The company expects to file the Form 10-Q within the five-calendar-day extension permitted under Rule 12b-25.

Insights

Corporate Reporting Analyst

Routine late-filing notice; company expects a short extension to complete quarter-end financials.

Apimeds cites the need to finalize the financial statements for the quarter ended March 31, 2026 and invokes the five-calendar-day extension under Rule 12b-25. This is an administrative filing that preserves compliance while the company finishes its accounting work.

Timing is explicit: the extension period is five calendar days. Subsequent filings will confirm whether any material change in results is reported; current disclosure says no anticipated significant change.

Key Figures

Commission File Number: 001-42545 Fiscal period end: March 31, 2026 Extension period: five calendar days +3 more

6 metrics

Commission File Number 001-42545 covering the registrant

Fiscal period end March 31, 2026 quarter ended

Extension period five calendar days Rule 12b-25 extension

EIN 85-1099700 issuer tax identifier

Registrant address city Matawan, New Jersey principal executive office

Filing signature date May 15, 2026 signature by CFO Erick Frim

Key Terms

Rule 12b-25, Form 10-Q, five-calendar-day extension

3 terms

Rule 12b-25 regulatory

"expects to file the Form 10-Q within the extension period of five calendar days"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

five-calendar-day extension regulatory

"will file the Form 10-Q within the extension period of five calendar days"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Apimeds (APUS) file a Form 12b-25 for the quarter ended March 31, 2026?

Apimeds filed the Form 12b-25 because it is finalizing the financial statements for the quarter ended March 31, 2026. The company states it needs additional time to complete those statements before filing its Form 10-Q.

How long is the extension Apimeds (APUS) expects to use to file the 10-Q?

Apimeds expects to use the five-calendar-day extension allowed under Rule 12b-25. The company anticipates filing the Form 10-Q within that extension period following the prescribed due date.

Does the notice say Apimeds (APUS) expects material changes to results for the quarter?

The notice answers that no significant change in results is anticipated for the corresponding period. The Form 12b-25 includes a checkbox question and the company did not indicate anticipated material changes.

Who signed the late-filing notification for Apimeds (APUS)?

The Form 12b-25 was signed by Erick Frim, Chief Financial Officer, and dated May 15, 2026. Contact telephone is listed as 215-499-1355 in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(CHECK ONE):	☐ Form 10-K	☐ Form 20-F	☐ Form 11-K	☒ Form 10-Q	☐ Form 10-D
	☐ Form N-CEN	☐ Form N-CSR

Commission File Number: 001-42545

For Period Ended: March 31, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ Transition Report on Form N-SAR

For the Transaction Period Ended: ______________

READ INSTRUCTION (ON BACK PAGE) BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Apimeds Pharmaceuticals US, Inc.

Full Name of Registrant

Former Name if Applicable

100 Matawan Rd, Suite 325

Address of Principal Executive Office (Street and Number)

Matawan, New Jersey 07747

City, State and Zip Code

001-42545		85-1099700
(Commission File Number)		(IRS Employer Identification No.)

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

		(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒		(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
		(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “Form 10-Q”) by the prescribed due date because the Company is in the process of finalizing the financial statements for the fiscal quarter ended March 31, 2026, and will need additional time to complete such financial statements. The Company anticipates that it will file the Form 10-Q within the extension period of five calendar days as provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

PART IV – OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Erick Frim		215		499-1355
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No
	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

1

Apimeds Pharmaceuticals US, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2026	By:	/s/ Erick Frim
	Name:	Erick Frim
	Title:	Chief Financial Officer

2